Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hysterectomy | 2 | 2022 | 80 | 0.800 |
Why?
|
| Dysmenorrhea | 1 | 2021 | 1 | 0.780 |
Why?
|
| Endometriosis | 1 | 2021 | 19 | 0.770 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 41 | 0.770 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 50 | 0.740 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 277 | 0.640 |
Why?
|
| Child Mortality | 1 | 2016 | 2 | 0.560 |
Why?
|
| Cause of Death | 1 | 2016 | 66 | 0.550 |
Why?
|
| Hospital Mortality | 1 | 2016 | 146 | 0.520 |
Why?
|
| Cost-Benefit Analysis | 4 | 2022 | 108 | 0.470 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2021 | 17 | 0.440 |
Why?
|
| Female | 8 | 2022 | 14466 | 0.230 |
Why?
|
| Adolescent | 3 | 2021 | 2957 | 0.220 |
Why?
|
| United States | 4 | 2022 | 2032 | 0.210 |
Why?
|
| Endometrial Hyperplasia | 1 | 2022 | 6 | 0.200 |
Why?
|
| Oncologists | 1 | 2022 | 15 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 309 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 44 | 0.200 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2021 | 1 | 0.200 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 33 | 0.190 |
Why?
|
| Macaca mulatta | 1 | 2021 | 47 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 72 | 0.190 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2020 | 5 | 0.180 |
Why?
|
| Trastuzumab | 1 | 2020 | 12 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 96 | 0.180 |
Why?
|
| Adult | 3 | 2021 | 7384 | 0.180 |
Why?
|
| Ethanol | 1 | 2021 | 118 | 0.180 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 31 | 0.180 |
Why?
|
| Middle Aged | 2 | 2021 | 6820 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2022 | 184 | 0.180 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 70 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2021 | 386 | 0.170 |
Why?
|
| Humans | 8 | 2022 | 26846 | 0.170 |
Why?
|
| Cohort Studies | 1 | 2021 | 859 | 0.160 |
Why?
|
| Quality of Life | 1 | 2021 | 464 | 0.150 |
Why?
|
| Hematometra | 1 | 2016 | 1 | 0.140 |
Why?
|
| Dilatation and Curettage | 1 | 2016 | 4 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 367 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2021 | 604 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 34 | 0.140 |
Why?
|
| Ethiopia | 1 | 2016 | 9 | 0.140 |
Why?
|
| Uterus | 1 | 2016 | 31 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2016 | 34 | 0.140 |
Why?
|
| Developing Countries | 1 | 2016 | 45 | 0.140 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 30 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 117 | 0.120 |
Why?
|
| Young Adult | 1 | 2021 | 2582 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2016 | 844 | 0.110 |
Why?
|
| Infant | 1 | 2016 | 957 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2016 | 1091 | 0.110 |
Why?
|
| Competency-Based Education | 1 | 2011 | 16 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2011 | 13 | 0.100 |
Why?
|
| General Surgery | 1 | 2011 | 53 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 139 | 0.090 |
Why?
|
| Child | 1 | 2016 | 2147 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2016 | 2433 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2011 | 224 | 0.080 |
Why?
|
| Male | 2 | 2016 | 12874 | 0.050 |
Why?
|
| Fetal Development | 1 | 2021 | 21 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 104 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 16 | 0.050 |
Why?
|
| Placenta | 1 | 2021 | 74 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 32 | 0.050 |
Why?
|
| Carboplatin | 1 | 2020 | 106 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 183 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 456 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 1131 | 0.040 |
Why?
|
| Nausea | 1 | 2016 | 16 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 13 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1394 | 0.030 |
Why?
|
| Program Development | 1 | 2011 | 75 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 102 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 162 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2264 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 204 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 262 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 910 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 918 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 9962 | 0.020 |
Why?
|